Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:December 19, 2017Completed
Hide Studies Not Open or Pending
Condition(s):Multiple MyelomaLast Updated:December 19, 2017Completed
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:December 16, 2019Completed
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:August 2, 2021Completed
Condition(s):Multiple MyelomaLast Updated:June 11, 2021Completed
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma; t(11;14) NegativeLast Updated:March 26, 2019Withdrawn
Condition(s):Multiple Myeloma; Multiple Myeloma in Relapse; Neoplasms; Gammopathy, Monoclonal; Paraproteinemias; Blood Protein Disorders; Haematologic Disease; Corneal Disease; Neoplasms, Plasma CellLast Updated:October 17, 2022Not yet recruiting
Condition(s):Multiple MyelomaLast Updated:May 16, 2023Active, not recruiting
Condition(s):Multiple MyelomaLast Updated:May 20, 2008Completed
Condition(s):Multiple MyelomaLast Updated:January 13, 2012Completed
Condition(s):Multiple MyelomaLast Updated:August 8, 2013Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.